The efficacy of withdrawal therapy in subjects with chronic daily headache and medication overuse following prophylaxis with topiramate and amitriptyline
- 13 May 2010
- journal article
- Published by Springer Nature in Neurological Sciences
- Vol. 31 (S1) , 175-177
Abstract
Management of patients affected by chronic daily headache (CDH) with medication overuse constitutes one of the most important unresolved problems. The uncertainty regarding the classification and the prophylaxis are a remarkable part of this problem. Objectives are to: (1) to evaluate the efficacy of withdrawal therapy following prophylaxis with topiramate and amitriptyline in a population affected by CDH and medication overuse with follow-up at 1 (T1), 3 (T2) and 6 (T3) months; (2) to identify which group of the Silberstein’s CDH classification (1994) may benefit from this protocol. Inclusion criteria are patients with CDH (headache for more >15 days/month for at least 3 consecutive months) and medication overuse according with IHS second edition (8.2 group); exclusion criteria are patients with secondary headache. All patients included in the study were hospitalized for 1 week. Type of overuse: combination of medications, 38%; analgesics, 29%; triptans, 29%; opioids, 2%; ergotamines, 2%. During hospitalization the following protocol was applied: desametasone 4 mg i.v./day for 1 week, diazepam 6 mg/day for 10 days and prophylaxis with amitriptylin plus topiramate. This prophylaxis was protracted for at least 6 months. The dosages assumed ranged for amitriptylin from 10 to 20 mg/day and for topiramate from 50 to 100 mg/day. In the last 4 years 105 patients with CDH (age 24–89 years; f 96; m 9) were admitted to the hospital. The protocol was applied in 52 patients (age, 29–65 years; f 49; m 3). At T1, 89% of the patients did not fall again into medication overuse; at T2, 64%; and at T3,45% of the patients remained free from overuse. According to the Silberstein’ proposal at T1, 93% of the subjects was affected by transformed migraine; and 7% by tension-type headache. At T3, all the patients free from overuse were affected by transformed migraine. Our data suggest that the patients affected by CDH and medication overuse benefit from withdrawal therapy performed during hospitalization plus prophylaxis with amitriptyline plus topiramate. This combination seems a good pharmacological solution to reduce the risk of relapse.Keywords
This publication has 13 references indexed in Scilit:
- The Evolution of Chronic Migraine: Classification and NomenclatureHeadache: The Journal of Head and Face Pain, 2009
- Topiramate Reduces Headache Days in Chronic Migraine: A Randomized, Double-Blind, Placebo-Controlled StudyCephalalgia, 2007
- Medication-overuse headache: Description, treatment, and relapse preventionCurrent Pain and Headache Reports, 2006
- Medication Overuse Headache (MOH) is a Biobehavioural DisorderCephalalgia, 2005
- Botulinum Toxin Type A for the Prophylaxis of Chronic Daily Headache: Subgroup Analysis of Patients Not Receiving Other Prophylactic Medications: A Randomized Double‐Blind, Placebo‐Controlled StudyHeadache: The Journal of Head and Face Pain, 2005
- Botulinum Toxin Type A (BOTOX ® ) for the Prophylactic Treatment of Chronic Daily Headache: A Randomized, Double‐Blind, Placebo‐Controlled TrialHeadache: The Journal of Head and Face Pain, 2005
- Medication-overuse headache: a worldwide problemThe Lancet Neurology, 2004
- Prophylaxis of Migraine, Transformed Migraine, and Cluster Headache with TopiramateHeadache: The Journal of Head and Face Pain, 2002
- Epidemiology of Chronic Daily Headache in the General PopulationHeadache: The Journal of Head and Face Pain, 1999
- Classification of Daily and Near‐Daily Headaches: Proposed Revisions to the IHS CriteriaHeadache: The Journal of Head and Face Pain, 1994